S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
$3.36
-1.2%
$3.25
$1.72
$3.84
$31.58M1.4927,771 shs21,644 shs
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$2.26
-6.2%
$2.89
$1.11
$3.53
$145.34M2.18393,232 shs763,637 shs
LifeVantage Co. stock logo
LFVN
LifeVantage
$5.75
-7.1%
$6.58
$3.04
$8.69
$79.66M0.7822,962 shs24,932 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$18.54
-2.5%
$18.78
$9.86
$21.72
$348.92M0.8251,338 shs60,355 shs
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$1.16
$0.98
$4.95
$69.47M2.34396,682 shs296,500 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-1.32%-1.18%-0.59%+29.73%+19.20%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-6.04%-12.93%-11.91%-22.51%+53.40%
LifeVantage Co. stock logo
LFVN
LifeVantage
-7.11%-6.35%-17.86%+2.86%+71.13%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-2.52%-6.65%-7.81%+3.92%+80.17%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.3431 of 5 stars
3.55.00.00.03.50.81.3
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
4.0413 of 5 stars
3.52.00.04.63.01.70.6
LifeVantage Co. stock logo
LFVN
LifeVantage
3.1405 of 5 stars
0.05.01.72.73.71.71.3
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.3598 of 5 stars
3.55.00.00.02.71.71.3
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
3.00
Buy$6.0078.57% Upside
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
3.00
Buy$10.00343.46% Upside
LifeVantage Co. stock logo
LFVN
LifeVantage
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0029.45% Upside
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest NATR, LFVN, OSMT, ACST, and GLYC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/27/2024
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
2/22/2024
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
2/7/2024
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/A$9.14 per shareN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
$10K14,533.48N/AN/A$0.60 per share3.76
LifeVantage Co. stock logo
LFVN
LifeVantage
$213.40M0.35$0.48 per share11.94$2.71 per share2.12
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.78$1.56 per share11.92$8.36 per share2.22
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
$177.88M0.00N/A1.00$1.50 per share0.00

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
-$36.90M-$0.58N/AN/AN/AN/A-73.09%-64.38%5/1/2024 (Estimated)
LifeVantage Co. stock logo
LFVN
LifeVantage
$2.54M$0.2325.00N/A1.40%19.96%9.48%5/2/2024 (Estimated)
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7724.08N/A3.39%12.25%7.75%5/14/2024 (Estimated)
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
-$79.59M-$1.59N/AN/AN/A-138.76%-81.23%-20.97%N/A

Latest NATR, LFVN, OSMT, ACST, and GLYC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
2/12/202412/31/2023
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
-$0.23-$0.21+$0.02-$0.21N/AN/A
1/30/2024Q2 2024
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A$0.10+$0.10$0.25N/A$51.62 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/AN/AN/AN/AN/A
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/AN/AN/AN/AN/A
LifeVantage Co. stock logo
LFVN
LifeVantage
$0.142.43%N/A60.87%1 Years
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/AN/AN/AN/AN/A

Latest NATR, LFVN, OSMT, ACST, and GLYC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/25/2024
LifeVantage Co. stock logo
LFVN
LifeVantage
Quarterly$0.03502.64%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
N/A
15.19
15.19
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
N/A
6.41
6.41
LifeVantage Co. stock logo
LFVN
LifeVantage
N/A
1.68
1.03
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
N/A
0.43
0.42

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
6.08%
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
75.19%
LifeVantage Co. stock logo
LFVN
LifeVantage
35.32%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
46.18%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acasti Pharma Inc. stock logo
ACST
Acasti Pharma
329.40 million8.13 millionNot Optionable
GlycoMimetics, Inc. stock logo
GLYC
GlycoMimetics
3864.45 million58.84 millionOptionable
LifeVantage Co. stock logo
LFVN
LifeVantage
24812.87 million12.00 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.90 millionOptionable
Osmotica Pharmaceuticals plc stock logo
OSMT
Osmotica Pharmaceuticals
30262.59 million59.32 millionNot Optionable

NATR, LFVN, OSMT, ACST, and GLYC Headlines

SourceHeadline
Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Inc.
wsj.com - March 6 at 4:32 PM
RVL Pharmaceuticals PLC (RVLPQ)RVL Pharmaceuticals PLC (RVLPQ)
investing.com - December 19 at 9:08 AM
Other OTC Pharmaceuticals - SeychellesOther OTC Pharmaceuticals - Seychelles
statista.com - October 8 at 8:51 PM
Osmotica Pharmaceuticals is about to announce its earnings — heres what to expectOsmotica Pharmaceuticals is about to announce its earnings — here's what to expect
markets.businessinsider.com - August 14 at 1:21 AM
What Wall Street expects from Osmotica Pharmaceuticalss earningsWhat Wall Street expects from Osmotica Pharmaceuticals's earnings
markets.businessinsider.com - March 19 at 12:43 PM
GRO Biosciences Appoints Rakhshita Dhar to its Board of DirectorsGRO Biosciences Appoints Rakhshita Dhar to its Board of Directors
nz.finance.yahoo.com - January 19 at 9:21 PM
UPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceUPDATE – Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
finance.yahoo.com - January 19 at 3:55 PM
Osmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol RVLPOsmotica Pharmaceuticals Announces Corporate Name Change to RVL Pharmaceuticals plc With New Ticker Symbol 'RVLP'
benzinga.com - January 19 at 10:54 AM
Osmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales GuidanceOsmotica Pharmaceuticals plc Announces Corporate Name Change to RVL Pharmaceuticals plc, New Ticker Symbol “RVLP,” Plans to Launch UPNEEQ® into the Medical Aesthetics Market, and Provides Fourth Quarter 2022 Net Sales Guidance
finance.yahoo.com - January 19 at 10:54 AM
RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022RVL Pharmaceuticals to Host UPNEEQ® Overview and Business Update Webcast on January 19, 2022
finance.yahoo.com - January 18 at 7:56 AM
Fresh Insights On Osmotica Pharmaceuticals plc (OSMT)Fresh Insights On Osmotica Pharmaceuticals plc (OSMT)
stocksregister.com - January 15 at 6:25 PM
Osmotica Pharmaceuticals plc (OSMT): What Is Good About Stock?Osmotica Pharmaceuticals plc (OSMT): What Is Good About Stock?
marketingsentinel.com - January 11 at 7:36 AM
Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022Osmotica Pharmaceuticals plc to Host UPNEEQ® Overview and Business Update Call on January 19, 2022
finance.yahoo.com - January 6 at 9:24 AM
Boom Or Bust: What Are Osmotica Pharmaceuticals plc’s (NASDAQ:OSMT) Future Prospects?Boom Or Bust: What Are Osmotica Pharmaceuticals plc’s (NASDAQ:OSMT) Future Prospects?
marketingsentinel.com - January 1 at 10:28 AM
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Shares Rose Recently. However, Trouble May Still Be Lurking.Osmotica Pharmaceuticals plc (NASDAQ: OSMT) Shares Rose Recently. However, Trouble May Still Be Lurking.
stocksregister.com - December 27 at 12:57 PM
Osmotica Pharmaceuticals plc (NASDAQ: OSMT): Why Investors Shouldn’t Ditch OSMT Stock In 2021Osmotica Pharmaceuticals plc (NASDAQ: OSMT): Why Investors Shouldn’t Ditch OSMT Stock In 2021
marketingsentinel.com - December 27 at 12:57 PM
Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Shares Plunged 0.00% In A Week – But Will They Keep Going Up?Osmotica Pharmaceuticals plc (NASDAQ:OSMT) Shares Plunged 0.00% In A Week – But Will They Keep Going Up?
marketingsentinel.com - December 23 at 2:40 PM
James Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More SharesJames Schaub Is The Executive VP & COO of Osmotica Pharmaceuticals plc (NASDAQ:OSMT) And They Just Picked Up 30% More Shares
nasdaq.com - December 22 at 2:02 PM
Osmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect ConferenceOsmotica Pharmaceuticals plc to Present at H.C. Wainwright Bioconnect Conference
finance.yahoo.com - December 20 at 6:40 PM
Osmotica Pharmaceuticals plc (NASDAQ: OSMT):The Stock Was Down -2.04 Percent From Its Lows On Friday, So What’s To Come?Osmotica Pharmaceuticals plc (NASDAQ: OSMT):The Stock Was Down -2.04 Percent From Its Lows On Friday, So What’s To Come?
marketingsentinel.com - December 18 at 6:32 PM
Osmotica Pharmaceuticals EPS Diluted (5 Year Growth)Osmotica Pharmaceuticals EPS Diluted (5 Year Growth)
ycharts.com - December 18 at 12:57 AM
Osmotica Pharmaceuticals plc (OSMT) Could Be Sitting On A GoldmineOsmotica Pharmaceuticals plc (OSMT) Could Be Sitting On A Goldmine
stocksregister.com - December 4 at 10:20 AM
What Analysts Were Expecting After Osmotica Pharmaceuticals plc (NASDAQ: OSMT) rose 2.76%What Analysts Were Expecting After Osmotica Pharmaceuticals plc (NASDAQ: OSMT) rose 2.76%
stocksregister.com - November 25 at 2:06 PM
The Future Of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) In 2021The Future Of Osmotica Pharmaceuticals plc (NASDAQ: OSMT) In 2021
stocksregister.com - November 18 at 9:51 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acasti Pharma logo

Acasti Pharma

NASDAQ:ACST
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.
GlycoMimetics logo

GlycoMimetics

NASDAQ:GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
LifeVantage logo

LifeVantage

NASDAQ:LFVN
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.
Osmotica Pharmaceuticals logo

Osmotica Pharmaceuticals

NASDAQ:OSMT
Osmotica Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.